SCNI

Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc. Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices...

Prof. Michael Schn, Director of Dermatology and Venereology at the University Medical Center Gttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board Prof. Michael Schn...

Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million Scinai Publishes Financial Results and...

Scinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024 Scinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline...

Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and...

Scinai Regains Full Compliance with Nasdaq Listing Requirements Scinai Regains Full Compliance with Nasdaq Listing Requirements PR Newswire JERUSALEM, Aug. 29, 2024 JERUSALEM, Aug. 29, 2024...

Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000 Scinai...

Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with...

Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23 Scinai Publishes Q2 2024...